Battle of the pain blocks: which injection wins after Weight-Loss surgery?
NCT ID NCT06349772
First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time
Summary
This trial compares two FDA-approved long-acting local anesthetics, Zynrelef and Exparel, for controlling pain after robotic sleeve gastrectomy. About 130 adults aged 18-65 scheduled for this surgery will receive one of the two drugs injected at the surgical site. Researchers will measure pain scores and total opioid use for up to 72 hours after surgery to see which drug provides better relief.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Zynrelef (bupivacaine and meloxicam) and Exparel (liposomal bupivacaine)
- What this could lead to
- If one drug works better, it could mean less pain and less need for opioids after weight-loss surgery.
- What could go wrong
- This is a very early-stage trial with only 130 people, so results may not apply to everyone. Both drugs are already approved, so the benefit over existing options may be small.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Texas Tech University Health Sciences Center
RECRUITINGLubbock, Texas, 79430, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Timing your meals or halving your rice: a new trial tests simple diet hacks for weight loss and blood sugar control
- Does injection location matter for a new Weight-Loss drug? a trial investigates
- Can a new drug boost Semaglutide's power against diabetes and obesity?
- Can a Normal-Weight baseline improve heart risk assessment in type 1 diabetes?
- A daily pill for obesity? zenagamtide faces its biggest test yet.
- Dance and walking may boost heart health in obesity — a trial puts it to the test